ADICON HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.21 HKD | -2.38% |
|
-0.61% | -37.04% |
| Sales 2024 * | 3.58B 495M 3.87B 41.29B | Sales 2025 * | 4.47B 618M 4.83B 51.57B | Capitalization | 5.54B 765M 5.97B 63.8B |
|---|---|---|---|---|---|
| Net income 2024 * | 375M 51.81M 405M 4.32B | Net income 2025 * | 549M 75.85M 592M 6.33B | EV / Sales 2024 * | 1.16 x |
| Net cash position 2024 * | 1.39B 192M 1.5B 16.04B | Net cash position 2025 * | 1.58B 218M 1.7B 18.19B | EV / Sales 2025 * | 0.88 x |
| P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
10.7
x | Employees | 5,713 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.26% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.38% | ||
| 1 week | -0.61% | ||
| Current month | +0.37% | ||
| 1 month | -6.92% | ||
| 3 months | -24.95% | ||
| 6 months | -34.42% | ||
| Current year | -37.04% |
1 week
8.10
8.56
1 month
7.509.46
Current year
7.5013.48
1 year
7.5019.18
3 years
7.5019.18
5 years
7.5019.18
10 years
7.5019.18
| Managers | Title | Age | Since |
|---|---|---|---|
Song Gao
CEO | Chief Executive Officer | 52 | 16/19/16 |
Lawrence Wang
DFI | Director of Finance/CFO | 47 | 09/20/09 |
Dan Li
PRN | Corporate Officer/Principal | 45 | 19/19/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Yeh
BRD | Director/Board Member | 56 | 24/21/24 |
Jixun Lin
FOU | Founder | 59 | 01/04/01 |
Jun Yuan Feng
BRD | Director/Board Member | 55 | 12/20/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/24/12 | 8.21 | -2.38% | 70,500 |
| 11/24/11 | 8.41 | -0.47% | 121,000 |
| 07/24/07 | 8.45 | +3.05% | 146,000 |
| 06/24/06 | 8.2 | -3.64% | 214,500 |
| 05/24/05 | 8.51 | +3.03% | 385,000 |
Delayed Quote Hong Kong S.E., June 12, 2024 at 01:38 pm IST
More quotes
Adicon Holdings Ltd is an investment holding company principally engaged in the provision of independent clinical laboratory (ICL) services. The Company primarily provides testing services to hospitals, medical institutions, medical examination centers, consumers, pharmaceutical companies and contract research organizations (CROs). The Company's inspection services mainly include routine tests, esoteric tests, clinical immunologic testing, clinical chemistry testing, clinical molecular biology testing, pathology testing and others testing. The Company is also engaged in the sales of medical testing equipment. The Company principally conducts its businesses in the domestic market.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.612
CNY
Average target price
14.38
CNY
Spread / Average Target
+88.91%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.04% | 783M | |
| -22.07% | 7.87B | |
| +77.60% | 4.52B | |
| +6.76% | 2.78B | |
| -2.80% | 2.62B | |
| -49.62% | 2B | |
| -13.10% | 1.68B | |
| -20.79% | 1.47B | |
| +16.24% | 1.22B | |
| -44.65% | 1.12B |
- Stock Market
- Equities
- 9860 Stock
